GAMMA Investing LLC Acquires 6,508 Shares of Johnson & Johnson $JNJ

GAMMA Investing LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 9.0% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 78,530 shares of the company’s stock after purchasing an additional 6,508 shares during the period. Johnson & Johnson makes up approximately 0.7% of GAMMA Investing LLC’s portfolio, making the stock its 20th biggest holding. GAMMA Investing LLC’s holdings in Johnson & Johnson were worth $19,944,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Greenberg Financial Group bought a new stake in shares of Johnson & Johnson in the 4th quarter worth $954,000. World Investment Advisors lifted its position in shares of Johnson & Johnson by 19.6% during the fourth quarter. World Investment Advisors now owns 161,343 shares of the company’s stock valued at $33,390,000 after purchasing an additional 26,450 shares in the last quarter. Benchmark Financial LLC purchased a new position in Johnson & Johnson during the fourth quarter worth about $554,000. Robinhood Asset Management LLC purchased a new position in Johnson & Johnson during the fourth quarter worth about $11,853,000. Finally, Principal Financial Group Inc. grew its position in Johnson & Johnson by 0.8% in the 4th quarter. Principal Financial Group Inc. now owns 3,410,177 shares of the company’s stock worth $705,736,000 after purchasing an additional 28,370 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts have commented on JNJ shares. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a research report on Monday. Wells Fargo & Company increased their price target on Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research report on Monday. JPMorgan Chase & Co. lifted their price target on Johnson & Johnson from $250.00 to $260.00 and gave the stock a “neutral” rating in a report on Wednesday, April 15th. Royal Bank Of Canada upped their price objective on Johnson & Johnson from $265.00 to $287.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, Citigroup raised their target price on Johnson & Johnson from $285.00 to $298.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $267.48.

Johnson & Johnson Trading Up 0.3%

Shares of JNJ stock opened at $255.26 on Wednesday. The company has a quick ratio of 0.81, a current ratio of 1.09 and a debt-to-equity ratio of 0.44. The firm has a market cap of $615.15 billion, a P/E ratio of 29.58, a PEG ratio of 2.41 and a beta of 0.24. The company has a 50 day moving average of $246.74 and a 200-day moving average of $239.05. Johnson & Johnson has a 12-month low of $169.65 and a 12-month high of $274.90.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.84 by $0.06. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.The business had revenue of $25.31 billion for the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter in the prior year, the business earned $2.77 earnings per share. Johnson & Johnson’s revenue for the quarter was up 6.6% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.69 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th will be given a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio is currently 62.11%.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: FDA authorization opens a new growth avenue: The FDA authorized J&J’s OTTAVA robotic surgical system, marking the company’s entry into surgical robotics. Investors view the platform as a potentially meaningful long-term growth driver and a way to diversify beyond pharmaceuticals and medical devices. Johnson & Johnson Gets FDA Nod for OTTAVA
• Positive Sentiment: Strong oncology performance supports earnings growth: Darzalex, Erleada and newer cancer treatments drove solid second-quarter oncology growth, reinforcing expectations that Innovative Medicine can offset pressure from products facing patent expirations. J&J recently exceeded quarterly EPS and revenue estimates and reaffirmed fiscal 2026 EPS guidance of $11.60-$11.75. J&J’s Strong Q2 Oncology Performance Fuels Future Growth Hopes
• Positive Sentiment: Higher analyst valuation: Wells Fargo raised its JNJ price target from $272 to $282 and maintained an Overweight rating, suggesting further upside based on the company’s earnings outlook and growth initiatives. Wells Fargo price-target report
• Neutral Sentiment: Leadership transition announced: Innovative Medicine chairman Jennifer Taubert will retire after more than 21 years with J&J. Tom Cavanaugh will succeed her as executive vice president and worldwide chairman in September. Taubert oversaw the division’s expansion to more than $60 billion in annual revenue, while the transition creates some execution uncertainty. Johnson & Johnson leadership change
• Neutral Sentiment: Competitive concerns appear limited: An analyst covering Intuitive Surgical characterized OTTAVA as a potential growth catalyst rather than a major competitive threat, reducing concerns that J&J’s entry will immediately disrupt the established robotics market. Analyst commentary on OTTAVA

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Vanessa Broadhurst sold 23,054 shares of the business’s stock in a transaction dated Monday, July 20th. The shares were sold at an average price of $251.27, for a total value of $5,792,778.58. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,779,963.81. This represents a 50.06% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.